Effect of allopurinol in preventing kidney damage due to coronary angiography

Effect of allopurinol in preventing contrast induced nephropathy among patients undergoing elective PCI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015120525372N1

Enrollment

200

Registered

2017-06-06

Start date

2012-10-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast induced nephropathy. X-ray contrast media

Interventions

Intervention 1: allopurinol, 600 mg PO, 24 hours before PCI. Intervention 2: placebo, 24 hours before PCI.

Treatment - Drugs

Placebo

allopurinol, 600 mg PO, 24 hours before PCI

placebo, 24 hours before PCI

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients undergoing elective PCI Exclusion criteria: Patients who are candidates for CABG or primary PCI; Patients with gout or prior use of allopurinol; Serum creatinin >3mg/dL or eGFR<60ml/min; Advanced hepatic failure; Patients who are using azathioprine, 6MP, or warfarin; Patients who have not filled/signed consent form, or the ones who had shown adverse reaction to the drug in prior use

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum cystatin C. Timepoint: 24 hours after PCI. Method of measurement: blood sample.;Serum creatinin. Timepoint: 24 hours after PCI. Method of measurement: blood sample.	—

Secondary

Measure	Time frame
Serum uric acid. Timepoint: 24 hours before and after PCI. Method of measurement: blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hajhossein Talasaz

Tehran Heart Center

ahhtalasaz@yahoo.com+98 21 8802 9610

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026